`
`
` NDA 021688/S-027
`
`
`
`SUPPLEMENT APPROVAL
`
`
`
` Amgen Inc.
`
` Attention: Juliana Sholter, MS
`
` RAC, Manager, Regulatory Affairs
`
` 60113th Street NW, Suite 1100 North
`
`
` Washington, DC 20005
`
`
`
`
`Dear Ms. Sholter:
`
`
`
`
`Please refer to your supplemental new drug application (sNDA) dated and received,
`May 28, 2019, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and
`
`
`Cosmetic Act (FDCA) for Sensipar (cinacalcet hydrochloride) tablets.
`
`
`
`
`
`
`This Prior Approval supplemental new drug application proposes the following change
`
`
`for Sensipar US Prescribing Information (PI): to include “Chondrocalcinosis
`
`
`pyrophosphate (acute pseudogout)" as an adverse drug reaction identified during post
`
`
`approval use of Sensipar to Section 6.2 Postmarketing Experience.
`
`
`APPROVAL & LABELING
`
`We have completed our review of this application, as amended. It is approved, effective
`
`
`
`on the date of this letter, for use as recommended in the enclosed agreed-upon
`
`labeling.
`
`
`CONTENT OF LABELING
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the
`
`
`
`content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using
`
`
`
`
`
`the FDA automated drug registration and listing system (eLIST), as described at
`
`
`
`
`FDA.gov.1 Content of labeling must be identical to the enclosed labeling (text for the
`
`Prescribing Information), with the addition of any labeling changes in pending “Changes
`
`
`Being Effected” (CBE) supplements, as well as annual reportable changes not included
`
`
`
`in the enclosed labeling.
`
`Information on submitting SPL files using eList may be found in the guidance for
`
`industry SPL Standard for Content of Labeling Technical Qs and As.2
`
`
`
`
`
`
`
`
` 1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
`
` 2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance
`
` Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`
`
`
`
`
`Reference ID: 4529665
`
`
`
`
`
`
`
`
` NDA 021688/S-027
` Page 2
`
`
`
`
` The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`Also within 14 days, amend all pending supplemental applications that include labeling
`
`
`changes for this NDA, including CBE supplements for which FDA has not yet issued an
`
`
`
`
`action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word
`
`
`
`format, that includes the changes approved in this supplemental application, as well as
`
`annual reportable changes. To facilitate review of your submission(s), provide a
`
`
`highlighted or marked-up copy that shows all changes, as well as a clean Microsoft
`
`Word version. The marked-up copy should provide appropriate annotations, including
`
`
`
`supplement number(s) and annual report date(s).
`
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for
`
`
`
`new active ingredients, new indications, new dosage forms, new dosing regimens, or
`
`
`
`new routes of administration are required to contain an assessment of the safety and
`
`
`effectiveness of the product for the claimed indication(s) in pediatric patients unless this
`
`
`
`
`
`requirement is waived, deferred, or inapplicable.
`
`
`
`
`Because none of these criteria apply to your application, you are exempt from this
`
`
`
`requirement.
`
`
`PROMOTIONAL MATERIALS
`
`
`You may request advisory comments on proposed introductory advertising and
`
`
`promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter
`
`
`requesting advisory comments, (2) the proposed materials in draft or mock-up form with
`
`annotated references, and (3) the Prescribing Information to:
`
`
`
`
`
`OPDP Regulatory Project Manager
`
`Food and Drug Administration
`
`Center for Drug Evaluation and Research
`
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`Alternatively, you may submit a request for advisory comments electronically in eCTD
`
`
`
`format. For more information about submitting promotional materials in eCTD format,
`
`
`
`
`
`see the draft guidance for industry Providing Regulatory Submissions in Electronic and
`
`
`
`Non-Electronic Format-Promotional Labeling and Advertising Materials for Human
`
`Prescription Drugs.3
`
`
` 3 When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent
` version of a guidance, check the FDA guidance web page at
`
`https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`U.S. Food and Drug Administration
`
`
`
`
`Silver Spring, MD 20993
`www.fda.gov
`
`
`
`
`Reference ID: 4529665
`
`
`
`
`
`
` NDA 021688/S-027
` Page 3
`
`
`
`
`
`
`
` You must submit final promotional materials and Prescribing Information, accompanied
`
` by a Form FDA 2253, at the time of initial dissemination or publication
`
`
`
` [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.4 Information and
`
`
`
`
`
`
`
`
`
`
`
`Instructions for completing the form can be found at FDA.gov.5 For more information
`about submission of promotional materials to the Office of Prescription Drug Promotion
`
`
`(OPDP), see FDA.gov.6
`
`
`REPORTING REQUIREMENTS
`
`
`
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`If you have any questions, call Meghna M. Jairath, Pharm.D., Regulatory Project
`
`
`Manager, at (301) 796-4267.
`
`
`
`
`
`
`
`
`
`
`
`
`Sincerely,
`
`
`
`{See appended electronic signature page}
`
`
`Anil Rajpal, M.D., M.P.H.
`
`
`Deputy Director for Safety (Acting)
`
`Division of Metabolism and Endocrinology Products
`
`Office of Drug Evaluation II
`
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`ENCLOSURE:
`
`
`• Content of Labeling
`
`
`o Prescribing Information
`
`
`4 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
`
`
`
` 5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
`
`
` 6 http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm
`
`
`
`
`U.S. Food and Drug Administration
`
`Silver Spring, MD 20993
`
`www.fda.gov
`
`
`
`Reference ID: 4529665
`
`
`
`Signature Page 1 of 1
`--------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically. Following this are manifestations of any and all
`electronic signatures for this electronic record.
`--------------------------------------------------------------------------------------------
`/s/
`------------------------------------------------------------
`
`ANIL K RAJPAL
`12/05/2019 06:00:33 PM
`
`Reference ID: 4529665
`
`